Skip to main content

GENELUX Corp

GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001231457

In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 6 sales; 77 institutions reported holding it in 13F filings for Q3 2026, worth $25.9M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$104.3M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $155.7K in total
6
13F holdersQ3 2026, +7 vs. previous quarter
77
13F valueReported value at the end of Q3 2026
$25.9M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$8.00K
0.0% year over year
Net income, FY2025
-$32.1M
No comparable prior period
Free cash flow, FY2025
-$26.4M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $32.1M (401812.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
4.53M
Shares sold short
Change
−113.4K
−2.4% vs. previous
Days to cover
8.32
At average daily volume

Superinvestors holding GNLX, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding GNLX at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by GENELUX Corp insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 5, 2026 (view filing)5:20 PM ETNov 32 daysCappello JosephChief Technical OfficerSSale−668$2.04−$1.36K−0.2%317.8K after
Nov 5, 2026 (view filing)5:20 PM ETNov 32 daysZindrick ThomasPresident and CEOSSale−3.09K$2.05−$6.32K−0.3%1.22M after
Nov 5, 2026 (view filing)5:20 PM ETNov 32 daysYu TonyChief Scientific OfficerSSale−668$2.01−$1.34K−0.3%258.0K after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysCappello JosephChief Technical OfficerSSale−10.3K$2.74−$28.1K−3.1%318.5K after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysZindrick ThomasPresident and CEOSSale−34.5K$2.67−$91.9K−2.7%1.23M after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysYu TonyChief Scientific OfficerSSale−9.68K$2.75−$26.7K−3.6%258.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayYu TonyChief Scientific OfficerSSale−653$2.94−$1.92K−0.2%268.4K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayCappello JosephChief Technical OfficerSSale−653$2.95−$1.92K−0.2%328.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayZindrick ThomasPresident and CEOSSale−3.02K$2.95−$8.91K−0.2%1.26M after
Jul 2, 2026 (view filing)4:35 PM ETJul 11 daySmither John WDirectorSSale−12.0K$2.91−$34.9K−11.6%91.4K after

Top 10 13F holders, Q3 2026

See all 77 holders

The largest institutional positions in GENELUX Corp at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding GNLX in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Woodward Diversified Capital, LLC2,378,755$6.02M2.36%+116,647+5.2%Added
Vanguard Capital Management LLC1,660,995$4.20M0.00%−16,729−1.0%Reduced
Bleichroeder LP1,380,666$3.49M0.34%00.0%Unchanged
BlackRock, Inc.433,267$1.10M0.00%−6,335−1.4%Reduced
Geode Capital Management, LLC428,593$1.08M0.00%−10,620−2.4%Reduced
CM Management, LLC400,000$1.01M0.68%00.0%Unchanged
Two Sigma Investments, LP300,081$759.2K0.00%+300,081New
Vanguard Fiduciary Trust Co256,029$647.8K0.00%+19,685+8.3%Added
Global Retirement Partners, LLC227,854$576.5K0.01%00.0%Unchanged
LPL Financial LLC157,157$397.6K0.00%−700−0.4%Reduced

Holders of 5% or more of GNLX

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of GENELUX Corp.

Largest holders of GNLX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Armistice Capital, LLC13G9.99%4.22M sharesNewNov 14, 20251 filingNov 14, 2025SEC
Szalay Aladar13G/A6.20%2.83M shares−2.00 ppfrom 8.20%Feb 2, 20245 filingsNov 4, 2026SEC